Specialty Visits and Testing Patterns Prior to IPF Diagnosis in Medicare Patients

Joshua Mooney, MD, MS^a; Eunice Chang, PhD^b; Deepa Lalla, PhD^c; Elya Papoyan, MPH^b; Sheila R. Reddy, PhD, RPh^b; John Stauffer, MD^d; Tingjian Yan, PhD^b; Michael S. Broder, MD, MSHS^b

PURPOSE

- Idiopathic pulmonary fibrosis (IPF) is a deadly, progressive, fibrotic lung disease
- Establishing accurate diagnosis of IPF is challenging.
- Median delay to diagnosis is 2.2 years.²
- Delayed access to a tertiary care center and accurate diagnosis is associated with higher mortality rates in IPF, independent of disease severity.²
- Recent advances make early treatment (and diagnosis) crucial, as antifibrotic treatments have been shown to slow disease progression.

OBJECTIVE

• To describe patterns of pulmonologist visits and testing, both proxies for respiratory symptoms, experienced by Medicare patients prior to receiving a claim-based diagnosis of IPF.

METHODS

Study Design and Data Source

 Retrospective cohort study of Medicare enrollees diagnosed with IPF in 2012. Medicare Research Identifiable Files (RIF – 100% sample) were analyzed for this study.

Patient Population

- Diagnosis of IPF was determined based on the presence of ICD-9-CM codes for IPF (and absence of other interstitial lung disease) in the claims and, the occurrence of chest computerized tomography (CT, including high-resolution chest CT [HRCT])^a, per ATS guidelines.³
- Inclusion criteria listed in Figure 1.

Study Measures

- Patient demographics, time to event, and cumulative proportions of IPF patients receiving first respiratory test and first pulmonologist visit within 5 baseline years preceding IPF diagnosis.
- Tests included chest X-ray, pulmonary function testing (e.g. spirometry), oxygen saturation, antinuclear antibodies (ANA)^b, six-minute walk test, arterial blood gas, fiberoptic bronchoscopy, lung biopsy, precipitin panel, and cardiopulmonary exercise testing.
- Distribution of CT scans per patient to show temporal patterns, such as repeated occurrence of tests before diagnosis and time frame of those tests.



^a Procedure codes for high-resolution and routine CT are the same. ^b Includes ANA, Rheumatoid Factor, DNA (DS) Antibodies, Sm and Sm/RNP Antibodies, Scleroderma Antibodies (Anti-SCL-70), and Sjögren's Antibodies (SSA, SSB).

Statistical Analysis

RESULTS

Demographics

Frequency of Testing and Visits prior to IPF Diagnosis

^a Stanford University, Stanford, CA; ^b Partnership for Health Analytic Research, LLC, Beverly Hills, CA; ^c Palo Alto Outcomes Research, Palo Alto, CA; ^d Genentech, Inc., South San Francisco, CA

• Descriptive statistics

 Kaplan-Meier curves showed proportions of first test/visit over time and time from test/visit until IPF diagnosis.

• We identified 7,306 Medicare patients newly diagnosed with IPF in 2012 (**Figure 1**).

Mean (SD) age was 80.8 (6.2) years; 48.7% were female; and all geographic regions were represented in the sample (Table

• The majority of patients were White (94.4%) followed by Black, Hispanic, Asian, and other/unknown patients (Table 1).

Table 1. Patient Demographics of Newly Diagnosed IPF Patients in Y2012 (N=7,306)	
Age (y) , mean (SD) [Median]	80.8 (6.2) [81]
Female , n (%)	3,559 (48.7)
Region , n (%)	
Midwest	1,880 (25.7)
Northeast	1,412 (19.3)
South	2,962 (40.5)
West/Other/ Unknown	1,052 (14.4)
Race , n (%)	
White	6,894 (94.4)
Black	212 (2.9)
Hispanic	56 (0.8)
Asian	40 (0.5)
Other/Unknown	104 (1.4)

• By definition, all patients received a CT scan prior to a claims-based diagnosis of IPF, as a CT scan (+/- lung biopsy) is essential to establishing an IPF diagnosis in clinical practice.

• The use of all respiratory-related tests increased immediately prior to diagnosis (Figure 4)

CT Scan

- The initial CT scans occurred throughout the 5 years prior to diagnosis, with 57.5% of first scans occurring more than 1 year prior to diagnosis, and 32.5% more than 3 years before diagnosis.
- Repeated scans (i.e., from year-to-year or following yearly gaps) were common over the years prior to a diagnosis (Figure 3).

Time from Testing and Visit to IPF Diagnosis

• The median was reached earliest for chest X-rays (48.1 months prior to diagnosis), followed by chest CTs (18.7 months prior to diagnosis), PFTs (10.7 months prior to diagnosis), and pulmonologist visits (3.4 months). Median time to any test was 51.5 months. (Figure 4).



• We are currently conducting an analysis with data covering the period following the introduction of anti-fibrotics. These data were not available at the time of the current study.



improved patient outcomes. All CT scans prior to diagnosis over these many years represent a potential missed opportunity to establish the diagnosis earlier.

REFERENCES

1. Raghu G, et al. *Lancet Respir Med*. 2014;2(7):566-572. 2. Lamas DJ, et al. Am J Respir Crit Care Med. 2011;184(7):842-847. Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6):788-824.



This study was sponsored by Genentech, Inc. and F. Hoffmann-La Roche Ltd. Research was conducted by Partnership for Health Analytic Research, LLC.